Search

Your search keyword '"Lebbé, Céleste"' showing total 863 results
Start Over Author "Lebbé, Céleste"
863 results on '"Lebbé, Céleste"'

153. Adaptive Methods: When and How Should They be Used in Clinical Trials?

Author

d’Andon, Anne, Bassompierre, François, Béhier, Jean-Michel, Belorgey, Chantal, Bénichou, Jacques, Berdeaux, Gilles, Bergougnoux, Loic, Bilbault, Pascal, Chassany, Olivier, Brentano, Christian Funck, Gersberg, Martha, Labreveux, Claire, Lassale, Catherine, Lebbé, Céleste, Lecocq, Brigitte, Lévy, Vincent, Montestruc, François, Morgan, Caroline, Nachbaur, Gaelle, Palestro, Brigitte, Paoletti, Xavier, Porcher, Raphaël, Raison, Anne, Spiess, Laurent, Strub, Nathalie, Vitzling, Christian, and Vray, Muriel

Published
2011
Full Text
View/download PDF

154. Les méthodes adaptatives : quand et comment les utiliser dans les essais cliniques ?

Author

d’Andon, Anne, Bassompierre, François, Béhier, Jean-Michel, Belorgey, Chantal, Bénichou, Jacques, Berdeaux, Gilles, Bergougnoux, Loic, Bilbault, Pascal, Chassany, Olivier, Brentano, Christian Funck, Gersberg, Martha, Labreveux, Claire, Lassale, Catherine, Lebbé, Céleste, Lecocq, Brigitte, Lévy, Vincent, Montestruc, François, Morgan, Caroline, Nachbaur, Gaelle, Palestro, Brigitte, Paoletti, Xavier, Porcher, Raphaël, Raison, Anne, Spiess, Laurent, Strub, Nathalie, Vitzling, Christian, and Vray, Muriel

Published
2011
Full Text
View/download PDF

156. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Author

Wolchok, Jedd D., primary, Chiarion-Sileni, Vanna, additional, Gonzalez, Rene, additional, Grob, Jean-Jacques, additional, Rutkowski, Piotr, additional, Lao, Christopher D., additional, Cowey, C. Lance, additional, Schadendorf, Dirk, additional, Wagstaff, John, additional, Dummer, Reinhard, additional, Ferrucci, Pier Francesco, additional, Smylie, Michael, additional, Butler, Marcus O., additional, Hill, Andrew, additional, Márquez-Rodas, Ivan, additional, Haanen, John B. A. G., additional, Guidoboni, Massimo, additional, Maio, Michele, additional, Schöffski, Patrick, additional, Carlino, Matteo S., additional, Lebbé, Céleste, additional, McArthur, Grant, additional, Ascierto, Paolo A., additional, Daniels, Gregory A., additional, Long, Georgina V., additional, Bas, Tuba, additional, Ritchings, Corey, additional, Larkin, James, additional, and Hodi, F. Stephen, additional

Published
2022
Full Text
View/download PDF

157. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis

Author

Zaremba, Anne, Kramer, Rafaela, De Temple, Viola, Bertram, Stefanie, Salzmann, Martin, Gesierich, Anja, Reinhardt, Lydia, Baroudjian, Barouyr, Sachse, Michael M., Mechtersheimer, Gunhild, Johnson, Douglas B., Weppler, Alison M., Spain, Lavinia, Loquai, Carmen, Dudda, Milena, Pföhler, Claudia, Hepner, Adriana, Long, Georgina V., Menzies, Alexander M., Carlino, Matteo S., Lebbé, Céleste, Enokida, Tomohiro, Tahara, Makoto, Bröckelmann, Paul J., Eigentler, Thomas, Kähler, Katharina C., Gutzmer, Ralf, Berking, Carola, Ugurel, Selma, Stadtler, Nadine, Sucker, Antje, Becker, Jürgen, Livingstone, Elisabeth, Meier, Friedegund, Hassel, Jessica C., Schadendorf, Dirk, Hanoun, Maher, Heinzerling, Lucie, and Zimmer, Lisa

Subjects
Medizinische Fakultät » Universitätsklinikum Essen » Westdeutsches Tumorzentrum Essen (WTZ) » Pädiatrische Hämatologie/Onkologie, Medizinische Fakultät » Universitätsklinikum Essen » Institut für Pathologie und Neuropathologie, Oncology, Medizin, malignant melanoma, immune checkpoint inhibition, neutropenia, ddc:610, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Dermatologie, adverse events, Original Research, hematotoxicity
Abstract

Introduction: Immune checkpoint inhibitors (ICI) are increasingly being used to treat numerous cancer types. Together with improved recognition of toxicities, this has led to more frequent identification of rare immune-related adverse events (irAE), for which specific treatment strategies are needed. Neutropenia is a rare hematological irAE that has a potential for a high mortality rate because of its associated risk of sepsis. Prompt recognition and timely treatment of this life-threatening irAE are therefore critical to the outcome of patients with immune-related neutropenia. Methods: This multicenter international retrospective study was conducted at 17 melanoma centers to evaluate the clinical characteristics, diagnostics, treatment, and outcomes of melanoma patients with grade 4 neutropenia (

Published
2021

160. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.

Author

Ascierto, Paolo A., Mandalà, Mario, Ferrucci, Pier Francesco, Guidoboni, Massimo, Rutkowski, Piotr, Ferraresi, Virginia, Arance, Ana, Guida, Michele, Maiello, Evaristo, Gogas, Helen, Richtig, Erika, Quaglino, Pietro, Lebbé, Céleste, Helgadottir, Hildur, Queirolo, Paola, Spagnolo, Francesco, Tucci, Marco, Del Vecchio, Michele, Gonzalez-Cao, Maria, and Minisini, Alessandro Marco

Subjects
PROTEIN kinase inhibitors, MELANOMA, DRUG administration, ANTINEOPLASTIC agents, CLINICAL trials, TREATMENT effectiveness, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, METASTASIS, TRANSFERASES, GENETIC mutation, PROGRESSION-free survival, NIVOLUMAB, CONFIDENCE intervals, BRAIN tumors, IPILIMUMAB
Abstract

Background: The impact of the order of treatment with checkpoint inhibitors or BRAF/MEK inhibitors on the development of brain metastases in patients with metastatic unresectable BRAF V600-mutant melanoma is unknown. The SECOMBIT trial examined the impact of the order of receipt of these treatments in such patients. Methods: In this three-arm trial, we reviewed patients without brain metastases who received the BRAF/MEK inhibitors encorafenib and binimetinib until they had progressive disease followed by the immune checkpoint inhibitors ipilimumab and nivolumab (arm A); or treatment with ipilimumab and nivolumab until they had progressive disease followed by encorafenib and binimetinib (arm B); or treatment with encorafenib and binimetinib for 8 weeks followed by ipilimumab and nivolumab until they had progressive disease followed by retreatment with encorafenib arm binimetinib (arm C). Results: Brain metastases were discovered during the trial in 23/69 patients in arm A, 11/69 in arm B, and 9/68 in arm C. At a median follow-up of 56 months, the 60-month brain metastases-free survival rates were 56% for arm A, 80% for arm B (hazard ratio [HR] vs. A: 0.40, 95% confidence interval [CI] 0.23 to 0.58), and 85% for arm C (HR vs. A: 0.35, 95% CI 0.16 to 0.76). Conclusions: In patients with unresectable metastatic melanoma, the treatment sequence of immune checkpoint inhibition followed by BRAF/MEK inhibitors was associated with longer periods of new brain metastases-free survival than the reverse sequence. A regimen in which immune checkpoint inhibition was sandwiched between BRAF/MEK inhibition also appeared to be protective against brain metastases. (ClinicalTrials.gov number NCT02631447.) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

163. Deux schémas posologiques de l’association nivolumab (NIVO) plus ipilimumab (IPI) dans le mélanome avancé : résultats à 3 ans de l’étude CheckMate 511

Author

Lebbé, Céleste, primary, Meyer, Nicolas, additional, Mortier, Laurent, additional, Márquez-Rodas, Iván, additional, Robert, Caroline, additional, Rutkowski, Piotr, additional, Butler, Marcus O., additional, Eigentler, Thomas, additional, Menzies, Alexander M., additional, Smylie, Michael, additional, Arance, Ana M., additional, Ascierto, Paolo Antonio, additional, Svane, Inge Marie, additional, Ajaz, Mazhar, additional, Khushalani, Nikhil I., additional, Lobo, Maurice, additional, Zoco, Jesus, additional, and Pigozzo, Jacopo, additional

Published
2021
Full Text
View/download PDF

164. Prise en charge des patients atteints de mélanome de stade III ou IV réséqué depuis l’arrivée de l’immunothérapie et de la thérapie ciblée en situation adjuvante en vie réelle

Author

Varey, Emilie, primary, Dalle, Stéphane, additional, Grange, Florent, additional, Leccia, Marie-Thérèse, additional, Bens, Guido, additional, Dalac-Rat, Sophie, additional, Maubec, Eve, additional, Geoffrois, Lionnel, additional, Skowron, François, additional, Crickx, Béatrice, additional, Misery, Laurent, additional, Celerier, Philippe, additional, Zehou, Ouidad, additional, Jouary, Thomas, additional, Khammari, Amir, additional, Lebbé, Céleste, additional, and Dréno, Brigitte, additional

Published
2021
Full Text
View/download PDF

165. Données en vie réelle des inhibiteurs de check-point dans le mélanome métastatique

Author

Frenard, Cecile, primary, Blanchet, Katleen, additional, Goussault, Romain, additional, He, Maxime, additional, Lecerf, Philippe, additional, Leccia, Marie-Thérèse, additional, Dalac-Rat, Sophie, additional, Montaudié, Henri, additional, Legoupil, Delphine, additional, Skowron, François, additional, Dereure, Olivier, additional, Lechevalier, Diane, additional, Lebbé, Céleste, additional, Varey, Emilie, additional, Khammari, Amir, additional, and Dreno, Brigitte, additional

Published
2021
Full Text
View/download PDF

166. Différentiel d’efficacité de l’immunothérapie selon le profil d’exposition solaire du site de survenue du mélanome primitif : étude de cohorte prospective multicentrique MELBASE

Author

Russo, David, primary, Dalle, Stéphane, additional, Dereure, Olivier, additional, Mortier, Laurent, additional, Dalac-Rat, Sophie, additional, Dutriaux, Caroline, additional, Leccia, Marie-Thérèse, additional, Legoupil, Delphine, additional, Montaudié, Henri, additional, Maubec, Eve, additional, De Quatrebarbes, Julie, additional, Arnault, Jean-Philippe, additional, Brocard, Florence Granel, additional, Saïag, Philippe, additional, Dreno, Brigitte, additional, Allayous, Clara, additional, Oriano, Bastien, additional, Lefevre, Wendy, additional, Lebbé, Céleste, additional, and Boussemart, Lise, additional

Published
2021
Full Text
View/download PDF

169. Risque de toxicité immunomédiée chez les patients avec antécédents d’auto-immunité traités par inhibiteurs de checkpoint pour un mélanome métastatique

Author

Plaçais, Léo, primary, Dalle, Stéphane, additional, Dereure, Olivier, additional, Trabelsi, Sabiha, additional, Dalac, Sophie, additional, Legoupil, Delphine, additional, Montaudié, Henri, additional, Arnault, Jean-Philippe, additional, De Quatrebarbes, Julie, additional, Saiag, Philippe, additional, Possenti, Florence Brunet -, additional, Lesimple, Thierry, additional, Maubec, Eve, additional, Aubin, François, additional, Brocard, Florence Granel -, additional, Grob, Jean-Jacques, additional, Stoebner, Pierre-Emmanuel, additional, Allayous, Clara, additional, Dreno, Brigitte, additional, Oriano, Bastien, additional, Dutriaux, Caroline, additional, Mortier, Laurent, additional, and Lebbé, Céleste, additional

Published
2021
Full Text
View/download PDF

172. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis

Author

Zaremba, Anne, primary, Kramer, Rafaela, additional, De Temple, Viola, additional, Bertram, Stefanie, additional, Salzmann, Martin, additional, Gesierich, Anja, additional, Reinhardt, Lydia, additional, Baroudjian, Barouyr, additional, Sachse, Michael M., additional, Mechtersheimer, Gunhild, additional, Johnson, Douglas B., additional, Weppler, Alison M., additional, Spain, Lavinia, additional, Loquai, Carmen, additional, Dudda, Milena, additional, Pföhler, Claudia, additional, Hepner, Adriana, additional, Long, Georgina V., additional, Menzies, Alexander M., additional, Carlino, Matteo S., additional, Lebbé, Céleste, additional, Enokida, Tomohiro, additional, Tahara, Makoto, additional, Bröckelmann, Paul J., additional, Eigentler, Thomas, additional, Kähler, Katharina C., additional, Gutzmer, Ralf, additional, Berking, Carola, additional, Ugurel, Selma, additional, Stadtler, Nadine, additional, Sucker, Antje, additional, Becker, Jürgen C., additional, Livingstone, Elisabeth, additional, Meier, Friedegund, additional, Hassel, Jessica C., additional, Schadendorf, Dirk, additional, Hanoun, Maher, additional, Heinzerling, Lucie, additional, and Zimmer, Lisa, additional

Published
2021
Full Text
View/download PDF

174. Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma

Author

de Masson, Adele, primary, Zimmermann, Clement, additional, Boisson, Marie, additional, Ram-Wolff, Caroline, additional, Sadoux, Aurélie, additional, Louveau, Baptiste, additional, Vignon, Dominique, additional, Rivet, Jacqueline, additional, Cayuela, Jean-Michel, additional, Dobos, Gabor, additional, Moins-Teisserenc, Hélène, additional, Roelens, Marie, additional, Gruber, Aurélia, additional, Lebbé, Céleste, additional, Bagot, Martine, additional, Battistella, Maxime, additional, and Mourah, Samia, additional

Published
2021
Full Text
View/download PDF

180. Liste des collaborateurs

Author

Abdelhak, Sonia, primary, Aractingi, Sélim, additional, Aubin, François, additional, Ben Salah, Afif, additional, Boubaker, Sémir, additional, Carsuzaà, Francis, additional, Johan, Chanal, additional, Chosidow, Olivier, additional, Couppié, Pierre, additional, Crickx, Béatrice, additional, Georges-Yves, De Carsalade, additional, Delaunay, Pascal, additional, Del Giuduce, Pascal, additional, Desruelles, François, additional, Descamps, Vincent, additional, Develoux, Michel, additional, Giao, Do-pham, additional, Doutre, Marie-Sylvie, additional, Ducournau, Corinne, additional, Ducroux, Émilie, additional, Dupin, Nicolas, additional, Dalenda, El euch, additional, Lara, El hayderi, additional, Euvrard, Sylvie, additional, Farhi, David, additional, Ferneiny, Marie, additional, Ferrier-rembert, Audrey, additional, Feuilhade, De chauvin Martine, additional, Guyot, Alexis, additional, Hubiche, Thomas, additional, Lebbé, Céleste, additional, Lenormand, Cédric, additional, Levy, Eve, additional, Lipsker, Dan, additional, Lortholary, Olivier, additional, Mahé, Antoine, additional, Martins gomes, Ciro, additional, Maubec, Ève, additional, Mebazaa, Amel, additional, Merklen-djafri, Carine, additional, Mokni, Mourad, additional, Morand, Jean-Jacques, additional, Mougin, Christiane, additional, Nikkels, Arjen, additional, Pagès, Cécile, additional, Parize, Perrine, additional, Peyrefitte, Christophe, additional, Piérard, Gérald, additional, Piérard-franchimont, Claudine, additional, Poirier, Jean-Paul, additional, Pradinaud, Roger, additional, Prétet, Jean-Luc, additional, Roux, Jennifer, additional, Rybojad, Michel, additional, Soutou, Boutros, additional, Trojjet, Sondes, additional, and Vilmer, Catherine, additional

Published
2014
Full Text
View/download PDF

182. Outcome of pretransplant melanoma after solid organ transplantation: an observational study

Author

Patras, Marion, primary, Decullier, Evelyne, additional, Lebbé, Céleste, additional, Delyon, Julie, additional, Dantal, Jacques, additional, Legendre, Christophe, additional, Mazloum, Manal, additional, Du Thanh, Aurélie, additional, Boukari, Feriel, additional, Morelon, Emmanuel, additional, Jullien, Denis, additional, Kanitakis, Jean, additional, and Ducroux, Emilie, additional

Published
2021
Full Text
View/download PDF

184. Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database

Author

Casarotto, Emilie, primary, Chandwani, Sheenu, additional, Mortier, Laurent, additional, Dereure, Olivier, additional, Dutriaux, Caroline, additional, Dalac, Sophie, additional, Scherrer, Emilie, additional, Lévy-Bachelot, Laurie, additional, Verdoni, Laetitia, additional, Farge, Gaëlle, additional, Allayous, Clara, additional, Oriano, Bastien, additional, Dalle, Stéphane, additional, and Lebbé, Céleste, additional

Published
2021
Full Text
View/download PDF

188. Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma

Author

Becquart, Ondine, primary, Oriano, Bastien, additional, Dalle, Stéphane, additional, Mortier, Laurent, additional, Leccia, Marie Thérèse, additional, Dutriaux, Caroline, additional, Dalac, Sophie, additional, Montaudié, Henri, additional, de Quatrebarbes, Julie, additional, Brunet-Possenti, Florence, additional, Saiag, Philippe, additional, Lesimple, Thierry, additional, Beylot-Barry, Marie, additional, Aubin, François, additional, Stoebner, Pierre Emmanuel, additional, Arnault, Jean Philippe, additional, Dreno, Brigitte, additional, Porcher, Raphael, additional, Lebbé, Céleste, additional, and Guillot, Bernard, additional

Published
2021
Full Text
View/download PDF

189. Systemic Treatment Initiation in Classical and Endemic Kaposi’s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study

Author

Benajiba, Lina, primary, Lambert, Jérôme, additional, La Selva, Roberta, additional, Cochereau, Delphine, additional, Baroudjian, Barouyr, additional, Roux, Jennifer, additional, Le Goff, Jérôme, additional, Pages, Cécile, additional, Battistella, Maxime, additional, Delyon, Julie, additional, and Lebbé, Céleste, additional

Published
2021
Full Text
View/download PDF

191. Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans

Author

Beaziz, Jessica, primary, Battistella, Maxime, additional, Delyon, Julie, additional, Farges, Cécile, additional, Marco, Oren, additional, Pages, Cécile, additional, Le Maignan, Christine, additional, Da Meda, Laetitia, additional, Basset-Seguin, Nicole, additional, Resche-Rigon, Matthieu, additional, Walter Petrich, Anouk, additional, Kérob, Delphine, additional, Lebbé, Céleste, additional, and Baroudjian, Barouyr, additional

Published
2021
Full Text
View/download PDF

193. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Author

Ascierto, Paolo Antonio, Del Vecchio, Michelle, Mackiewicz, Andrzej, Robert, Caroline, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Svane, Inge Marie, Mcneil, Catriona, Rutkowski, Piotr, Loquai, Carmen, Mortier, Laurent, Hamid, Omid, Bastholt, Lars, Dreno, Brigitte, Schadendorf, Dirk, Garbe, Claus, Nyakas, Marta, Grob, Jean Jacques, Thomas, Luc, Liszkay, Gabriella, Smylie, Michael, Hoeller, Christoph, Ferraresi, Virginia, Grange, Florent, Gutzmer, Ralf, Pikiel, Joanna, Hosein, Fareeda, Simsek, Burcin, Maio, Michele, Ascierto, Paolo Antonio, Del Vecchio, Michelle, Mackiewicz, Andrzej, Robert, Caroline, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Svane, Inge Marie, Mcneil, Catriona, Rutkowski, Piotr, Loquai, Carmen, Mortier, Laurent, Hamid, Omid, Bastholt, Lars, Dreno, Brigitte, Schadendorf, Dirk, Garbe, Claus, Nyakas, Marta, Grob, Jean Jacques, Thomas, Luc, Liszkay, Gabriella, Smylie, Michael, Hoeller, Christoph, Ferraresi, Virginia, Grange, Florent, Gutzmer, Ralf, Pikiel, Joanna, Hosein, Fareeda, Simsek, Burcin, and Maio, Michele

Abstract

Background We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety. Methods This randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS. Results At a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 months (95% CI 9.9 to 13.3) at 3 mg/kg (HR 0.84, 95% CI 0.71 to 0.99; p=0.04). In a subgroup analysis, median OS of patients with asymptomatic brain metastasis was 7.0 months (95% CI 4.0 to 12.8) in the 10 mg/kg group and 5.7 months (95% CI 4.2 to 7.0) in the 3 mg/kg group. In patients with wild-type or mutant BRAF tumors, median OS was 13.8 months (95% CI 10.2 to 17.0) and 33.2 months (95% CI 19.4 to 45.2) in the 10 mg/kg group, and 11.2 months (95% CI 9.2 to 13.8) and 19.7 months (95% CI 11.6 to 25.3) in the 3 mg/kg group, respectively. The incidence of grade 3/4 treatment-related AEs was 36% in the 10 mg/kg group vs 20% in the 3 mg/kg group, and deaths due to treatment-related AEs occurred in four (1%) and two patients (1%), respectively. Conclusions This 61-month follow-up of a phase III trial showed sustained long-term survival in patients with advanced melanoma who started metastatic treatment with ipilimumab monotherapy, and confirmed the significant benefit for those who received ipilimumab 10 mg/kg vs 3 mg/kg. These results suggest the emergence of a plateau in the OS curve, consistent with previous ipilimumab studies. Trial registration number NCT01515189.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results